Compare ON & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ON | ALNY |
|---|---|---|
| Founded | 1992 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9B | 38.4B |
| IPO Year | 2000 | 2004 |
| Metric | ON | ALNY |
|---|---|---|
| Price | $118.28 | $292.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 28 |
| Target Price | $65.29 | ★ $471.00 |
| AVG Volume (30 Days) | ★ 11.1M | 1.1M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 206.88 |
| EPS | N/A | ★ 2.33 |
| Revenue | ★ $5,878,300,000.00 | $1,037,418,000.00 |
| Revenue This Year | $7.93 | $52.67 |
| Revenue Next Year | $8.90 | $31.48 |
| P/E Ratio | ★ N/A | $126.31 |
| Revenue Growth | N/A | ★ 22.88 |
| 52 Week Low | $44.56 | $273.11 |
| 52 Week High | $134.92 | $495.55 |
| Indicator | ON | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 50.95 | 50.26 |
| Support Level | $51.30 | $284.69 |
| Resistance Level | $119.10 | $314.04 |
| Average True Range (ATR) | 7.56 | 9.72 |
| MACD | -1.40 | 0.78 |
| Stochastic Oscillator | 39.49 | 58.39 |
Onsemi is a supplier of power semiconductors and sensors focused on the automotive and industrial markets. Onsemi is the second-largest power chipmaker in the world and the largest supplier of image sensors to the automotive market. While the firm used to be highly vertically integrated, it now pursues a hybrid manufacturing strategy for flexible capacity. Onsemi is pivoting to focus on emerging applications like electric vehicles, autonomous vehicles, industrial automation, and renewable energy.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.